Improvement of Care & Outcome
Outcome of type 1 diabetes (T1D) can only be improved by further automation of insulin delivery. As part of a real-life technical evaluation of a new advanced hybrid closed-loop system, and in the middle of COVID-19 pandemic, we analyzed outcomes after 5 weeks of use.
Thirty-five T1D patients, who were already using a Medtronic Minimed (MM)670G hybrid closed-loop in Auto Mode for >3 months, were invited for real-life evaluation of the MM780G advanced hybrid closed-loop system. Due to COVID-19, education and change between systems were largely done by remote video sessions. We used CareLink-generated reports to compare the last week of 670G system use with the 5th week of 780G system use.
These results indicate the feasibility of switching from a MM670G to an MM780G system in remote education sessions under COVID-19 circumstances. A strong improvement of important glucometric data was seen in a relatively short timeframe, even in a selected group of patients with good baseline diabetes regulation.
For abstract click here (page A-17).
For poster click here.